New Drugs
Dexcom G6 gets FDA nod
The first integrated continuous glucose monitoring system suitable for patients as young as 2 ...
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
FROM THE LANCET Phase 3 data with siponimod, Novartis’ investigational treatment for multiple sclerosis, ...
FDA approves new option in Hodgkin lymphoma treatment
The Food and Drug Administration has approved brentuximab vedotin, in combination with chemotherapy, for ...
FDA approves subcutaneous immunoglobulin treatment for CIDP
The Food and Drug Administration has approved Hizentra as the first subcutaneously administered human ...
- Annual Meeting of The Endocrine Society
- Conference News
- Diabetes
- Frontline Medical News
- New Drugs
- Women's Health
VIDEO: Fezolinetant drops testosterone levels in PCOS
REPORTING FROM ENDO 2018 CHICAGO (FRONTLINE MEDICAL NEWS) – Testosterone levels dropped by one ...
Fruquintinib promising agent for advanced NSCLC
FROM JOURNAL OF CLINICAL ONCOLOGY Investigational agent fruquintinib holds promise as a third- or ...
- Conference News
- Critical Care Congress
- Frontline Medical News
- Infectious diseases
- New Drugs
- Primary Care
- Top News Stories
Dr. Paul E. Marik proclaims end to corticosteroid monotherapy for sepsis
REPORTING FROM CCC47 SAN ANTONIO (FRONTLINE MEDICAL NEWS) – While critical care specialists await ...
Hemophilia A treatment gains approval in Europe
The European Commission has approved emicizumab for routine prophylaxis of bleeding episodes in adults ...
FDA approves tests to screen for tickborne parasite in blood supply
The Food and Drug Administration has approved two new tests to screen whole blood ...
- ASCO Gastrointestinal Cancers Symposium
- Conference News
- Frontline Medical News
- Gastroenterology
- New Drugs
- Oncology
New treatment options emerge for intermediate, advanced HCC
REPORTING FROM THE 2018 GI CANCERS SYMPOSIUM SAN FRANCISCO (FRONTLINE MEDICAL NEWS) – Two ...
Arm-placement indication for CGM approved by FDA
The Food and Drug Administration has approved a new indication for the Guardian Sensor ...
Phase 2 study tests low-dose maintenance therapy for ALL
FROM CLINICALTRIALS.GOV Researchers at MD Anderson Cancer Center in Houston are studying the safety ...
Dual kinase inhibitor performs well in its first safety, efficacy study for atopic dermatitis
REPORTING FROM AAD 2018 SAN DIEGO (FRONTLINE MEDICAL NEWS) – A novel molecule that ...
